Leerink Partnrs Analysts Reduce Earnings Estimates for VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Leerink Partnrs cut their Q2 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a report issued on Wednesday, June 25th. Leerink Partnrs analyst D. Risinger now forecasts that the pharmaceutical company will post earnings of $3.59 per share for the quarter, down from their previous forecast of $3.78. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals’ Q4 2025 earnings at $4.87 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.76 EPS.

A number of other research firms have also recently weighed in on VRTX. Scotiabank lowered their price target on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a report on Tuesday, May 6th. Erste Group Bank lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Bank of America upped their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Wall Street Zen raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $511.62.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $441.30 on Friday. The stock has a market cap of $113.33 billion, a P/E ratio of -112.58 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The stock’s 50 day simple moving average is $454.50 and its 200 day simple moving average is $458.82. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently modified their holdings of VRTX. Activest Wealth Management bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $31,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $32,000. Finally, Truvestments Capital LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.